March 2016, Vol. 5, No. 2
Biomarker Panel Warrants More Study as Aid to Early CRC Detection
A panel of 4 blood-derived biomarkers showed promise as an aid to early detection of colorectal cancer (CRC), as reported at the 2016 Gastrointestinal Cancers Symposium.
The panel yielded a negative predictive value (NPV) exceeding 90% for CRC, the combination of CRC and high-risk adenomas, and CRC plus other cancers. The biomarker assay demonstrated fair to good performance characteristics associated with area under the receiver operating characteristic curve (AUC) ranging between 0.70 and 0.80.
“We have demonstrated that a panel of blood-based markers can significantly predict the probabilities of the chosen end points,” said Ib J. Christensen, MSc, a biostatistician at Hvidovre Hospital and the University of Copenhagen in Denmark. “In the future, we hope to improve the results by including new markers and performing alternative analytic approaches, such as the adaptive index model.”
Christensen presented findings from a study designed to evaluate combinations of existing biomarkers to aid in the detection of colorectal neoplasia. After optimizing the biomarker combination, investigators evaluated biomarker-based approaches to early detection of CRC.
The investigation began with the identification of 8 biomarkers with evidence suggesting associations with CRC. The 8 markers were: carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein (hs-CRP), alpha-fetoprotein, ferritin, galectin-3, cytokeratin fragment 21-1 (CyFra21-1), cancer antigen 19-9, and tissue inhibitor of metalloproteinase-1.
To evaluate the markers, investigators recruited adult patients referred for a first-ever colonoscopy in follow-up to symptoms suggesting the presence of colorectal neoplasia. Patients with a history of CRC were excluded.
Subsequently, usable blood samples were obtained from almost 4700 patients. Colonoscopy identified colon cancer in 319 patients, rectal cancer in 193, colonic adenomas in 515, rectal adenomas in 174, other types of cancer in 177, and nonmalignant findings in 1342 (such as diverticula and ulcerative colitis). The remaining 1978 patients had what Christensen described as “clean colons.”
Assessment of the blood samples produced a separation among the biomarkers in terms of their ability to detect the chosen end points. Investigators found that a panel of 4 biomarkers (CEA, hs-CRP, ferritin, and CyFra21-1) performed as well as a panel comprising all 8 biomarkers.
The final model included the 4 protein markers plus patient age and sex. For the end point of CRC cancer plus high-risk adenomas, the model had an AUC of 0.71. For CRC only, the performance improved to 0.81.
The investigators calculated specificity, positive predictive value (PPV), and NPV for different levels of sensitivity. With 90% sensitivity for CRC plus high-risk adenomas, the model had a specificity of 33%, a PPV of 25%, and an NPV of 93%. For 90% sensitivity to detect only CRC, the model had a specificity of 48%, a PPV of 18%, and an NPV of 97%. For CRC and other cancers, the panel had a PPV of 20% and an NPV of 96%.
High-risk patients with metastatic renal cell carcinoma (RCC) and venous tumor thrombus derived no benefit from cytoreductive nephrectomy and should be evaluated for clinical trials of systemic therapy, a retrospective multicenter review suggested.Patients with thrombus above the diaphragm had a median overall survival of 6.8 months after surgery, about a [ Read More ]
A Century of Medical Product Regulation: The Historic Framework for Personalized Medicine in Oncology
Progress in personalized medicine is currently taking place within a system of governmental regulation that was largely created before the term was even coined. Today’s regulatory framework, directed primarily by the Food and Drug Administration (FDA) and a handful of other federal and state agencies, was created incrementally over the [ Read More ]